Sign In
Buy EVOK
$11.00
+0 (+0%)
At Close: Mar 16, 2026
Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management
09:00am, Monday, 29'th Jan 2024
AUSTIN, Texas--(BUSINESS WIRE)--Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management.
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
08:30am, Monday, 27'th Nov 2023
SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
08:30am, Tuesday, 14'th Nov 2023
SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
Evoke Pharma Reports Third Quarter 2023 Financial Results
08:30am, Thursday, 09'th Nov 2023
38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superio
Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating
Evoke Pharma's Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting
08:30am, Wednesday, 18'th Oct 2023
SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
08:30am, Thursday, 14'th Sep 2023
SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with
Evoke Pharma Reports Second Quarter 2023 Financial Results
08:30am, Thursday, 10'th Aug 2023
40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compar
Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide
“Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” “Superiority of Nasal Spray Compared to Orall
Evoke Pharma, Inc. (EVOK) Q4 2022 Earnings Call Transcript
06:39pm, Tuesday, 21'st Mar 2023
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Gonyer - Chief Executive Officer Chri
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
08:30am, Wednesday, 15'th Mar 2023
SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with
Evoke Pharma, Inc. (EVOK) Q3 2022 Results - Earnings Call Transcript
08:46pm, Wednesday, 09'th Nov 2022
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q3 2022 Results Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations, DKB Partners David Gonyer - Pre
Evoke Pharma to Report Third Quarter Results on November 9, 2022
08:30am, Wednesday, 02'nd Nov 2022
SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced
Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference
08:30am, Tuesday, 06'th Sep 2022
SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today
